Hyperprolactinemia With Aripiprazole

Saraf, Gayatri ; Behere, Rishikesh V. ; Venkatasubramanian, Ganesan ; Rao, Naren P. ; Varambally, Shivarama ; Gangadhar, B. N. (2014) Hyperprolactinemia With Aripiprazole American Journal of Therapeutics, 21 (3). e80-e81. ISSN 1075-2765

Full text not available from this repository.

Official URL: http://doi.org/10.1097/MJT.0b013e3182456de7

Related URL: http://dx.doi.org/10.1097/MJT.0b013e3182456de7


Aripiprazole, due to its partial agonist activity at the D2 receptors, is often recommended as the drug of choice in patients who develop antipsychotic-induced hyperprolactinemia. We report a case of a female patient who developed hyperprolactinemia while on treatment with aripiprazole. This partial D2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities.

Item Type:Article
Source:Copyright of this article belongs tO Wolters Kluwer Health, Inc.
ID Code:118690
Deposited On:28 May 2021 06:10
Last Modified:28 May 2021 06:10

Repository Staff Only: item control page